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Abstract. The common acute lymphoblastic
leukemia antigen (CALLA) has been detected in biolog-
ical fluids using a radioimmunoassay based on the
inhibition of binding of 125I-labeled monoclonal anti-
CALLA antibody to glutaraldehyde-fixed NALM-1 cells.
With this assay, we showed first that CALLA was
released in culture fluids from NALM-1 and Daudi cell
lines but was absent from culture fluids from CALLA
negative cell lines. Then, we found that the sera of 34
out of 42 patients (81%) with untreated common acute
lymphoblastic leukemia (c-ALL) contained higher
CALLA levels than any of the 42 serum samples from
healthy controls. The specificity of these results was
further demonstrated by testing in parallel the sera from
48 patients with CALLA negative leukemias, including
26 acute myeloid leukemia (AML), 12 T-cell acute
lymphoblastic leukemia (T-ALL), and 10 acute undif-
ferentiated leukemia (AUL). All of these sera gave
negative results, except for one patient with AUL, who
had a significantly elevated circulating CALLA level,
and one patient with AML, who had a borderline
CALLA level, 3 SD over the mean of the normal sera.
Preliminary results suggest that circulating CALLA is
associated with membrane fragments or vesicles, since
the total CALLA antigenic activity was recovered in the
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pellet of the serum samples centrifuged at 100,000 g. In
addition, the CALLA-positive pellets contained an en-
zyme considered as a membrane marker, 5'-nucleotidase.
Evaluation of the clinical importance of repeated serum
CALLA determinations for the monitoring of c-ALL
patients deserves further investigation.
Introduction
The common acute lymphoblastic leukemia antigen (CALLA)'
has been described initially as a cell surface antigen present
on leukemic blasts in patients with the common type of acute
lymphoblastic leukemia (c-ALL) or with chronic myelocytic
leukemia in lymphoid blast crisis (1-7). In addition, normal
lymphocyte precursors appear to express CALLA, especially
during bone marrow regeneration (8), but this antigen has not
been detected on immature myeloid precursors (9). Outside
the hematopoietic system, CALLA has been identified on the
surface of tubular and glomerular fetal and adult kidney cells
(10) as well as on glioma (11) and melanoma (12) cells.
Biochemically, CALLA has been characterized as a single
polypeptide chain with an approximate molecular weight of
100 kD (13).
In this work, we report for the first time the presence of
CALLA in the serum of patients with c-ALL. The circulating
CALLA was detected by a newly developed radioimmunoassay
(RIA) based on the inhibition of binding of '251-labeled anti-
CALLA monoclonal antibody (MAb) to glutaraldehyde-fixed
1. Abbreviations used in this paper: AML, acute myeloid leukemia;
AUL, acute undifferentiated leukemia; c-ALL, common acute lympho-
blastic leukemia; CALLA, common acute lymphoblastic leukemia
antigen; MAb, monoclonal antibody; T-ALL, T-cell acute lymphoblastic
leukemia.
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NALM-1 cells (14). This MAb, designated A 12, has been
shown (15) to react with the same epitope as the known J5
MAb (16).
Methods
Patients and controls. Serum samples were obtained from 90 patients
with leukemia before any treatment. The leukemia cases consisted of
42 patients with c-ALL (identified by the presence of CALLA and Ia-
antigens on leukemic cells (17) as well as the absence of T-cell markers
(18)), 26 patients with acute myeloid leukemia (AML) (identified by
Sudan Black staining and naphtol AS-D chloroacetate esterase positivity),
12 patients with T-cell acute lymphoblastic leukemia (T-ALL) (identified
by the formation of rosettes with sheep erythrocytes and/or the
presence of T-cell markers defined by various MAb), and 10 patients
with acute undifferentiated leukemia (AUL) (classified by the absence
of known cytochemical or surface markers on poorly differentiated
blast). Additional controls consisted of serum samples from 42 unselected
healthy blood bank donors.
In all cases the serum was collected after blood coagulation,
followed by centrifugation at 2,000 g for 15 min. In two cases of c-
ALL with previously identified elevated serum CALLA levels, blood
samples were collected into three tubes; one without anticoagulant,
one with EDTA, and one with heparin. The tubes were stored at room
temperature, and serum or plasma was taken from each tube 1, 24,
and 48 h after blood collection (the centrifuged blood was mixed gently
after each removal of plasma or serum samples).
Monoclonal antibody and target cells. The MAb A-12 used in the
CALLA RIA was obtained from a fusion between lymphocytes of a
BALB/c mouse immunized with NALM-1 cells and cells from the
myeloma line P3-NSI/l-Ag4 (19). As previously reported (15), MAb
A12 is of IgG1 subclass and reacts with the same epitope as the first
described MAb anti-CALLA termed J5 (16). MAb A-12 was purified
from hybridoma ascitic fluid by ion exchange chromatography, and
labeled with 1251 by the chloramine T method.
Exponentially growing NALM-1 cells were fixed by a 10-min
incubation at 25°C in 0.12% glutaraldehyde. The fixed cells retained
their antigenicity for at least 1 mo when stored at 4°C in 0.15 M
phosphate-buffered saline, pH 7.4 (PBS), containing 5% fetal bovine
serum and 0.02% azide.
RIA. 30-40% of '25I-labeled MAb A-12 (50 nCi representing about
6 ng of protein) was cell-bound after a 5-h incubation with 5 X 104
glutaraldehyde-fixed NALM-1 cells at 4°C. This binding was quanti-
tatively inhibited up to 95% by NP-40 extracts of NALM-1 cells but
not by extracts from CALLA-negative lines as demonstrated by the
standard inhibition curve and controls presented in Fig. I A.
In the routine RIA procedure, radiolabeled MAb A-12 diluted in
50 jul of PBS containing 1 mg/ml of bovine serum albumin was
incubated for 16 h at 25°C with 50 ul of either 20 times concentrated
culture fluid from the NALM-1 cell line or dilutions of patients' sera.
50,000 glutaraldehyde-fixed NALM-1 cells were then added for a
further incubation of 16 h at 4°C. The cells were washed with PBS
containing I mg/ml of bovine serum albumin, and the cell-bound
radioactivity was measured in a gamma-counter. Dilutions of a reference
serum from a patient with a high CALLA level as well as from a pool
of serum from normal individuals were always tested in parallel to
calibrate each series of new serum samples to be analyzed.
Determination of S'-nucleotidase activity. Assay of 5'-nucleotidase
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Figure 1. Inhibition of binding of '25I-labeled monoclonal anti-
CALLA antibody to glutaraldehyde-fixed NALM-1 cells by standard
dilutions of NP-40 lysates (A) of NALM-I cells (- * -) or HL-60
cells (- A -) as well as by concentrated culture fluid (B) from two
CALLA-positive cell lines, NALM-I (- * -) and Daudi (- * ),
and two CALLA negative cell lines, HL-60 (- o -) and END-I
(- A -).
obtained by a 100,000 g centrifugation of I ml of patient serum or
200 Al of the serum supernatant were resuspended in 4 ml of 50 mM
Tris-HCl buffer, pH 7.5, containing 2 mM 5'-AMP and 8 mM MgCl2,
and incubated for 20 min at 37°C. The reaction was stopped by the
addition of 0.8 ml of 30% ice-cold trichloroacetic acid. The released
inorganic phosphate was measured colorimetrically at 820 nm on 2-
ml aliquots.
Results
In a first series of experiments, the newly developed CALLA
RIA was used to demonstrate the release of this antigen into
culture fluids by two cell lines, NALM-I (14) and Daudi (21),
known to express CALLA on the cell surface. As shown in
Fig. 1 B, 20 times concentrated culture fluids from NALM-1
and Daudi cell lines inhibited the CALLA RIA by 100 and
70%, respectively; whereas culture fluids from two CALLA-
negative cell lines, the promyelocytic leukemia line HL-60 and
the endometrial carcinoma line END- 1, gave only background
inhibition values of 15 and 18%.
Based on these results, the CALLA RIA was then used to
search for CALLA in serum samples obtained from 90 patients
with different types of acute leukemias. A serum sample from
each patient was obtained before any treatment and assayed
in duplicate at two different dilutions (1:1, 1:5). Individual
mean inhibition values for undiluted serum samples from 42
cases of c-ALL, 12 cases of T-ALL, 26 cases of AML, 10 cases
ofAUL, and 42 normal controls tested in parallel are presented
in Fig. 2. The mean inhibition for the control sera was 13.2%
with a SD of 7.3.
We selected an arbitrary limit of 35% inhibition (3 SD
over the mean inhibition value of the control sera) to opera-
tionally define positive and negative results. Under these
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Figure 2. Individual serum CALLA levels from 42 patients with
c-ALL, 12 with T-ALL, 26 with AML, 10 with AUL, and from 42
unselected normal blood donors. The results are expressed in per-
centages of inhibition of binding of '25I-labeled monoclonal anti-
CALLA antibody to NALM- I cells.
conditions, 34/42 (81%) cases of c-ALL were positive, whereas
none of the normal serum samples nor any of the 12 cases of
T-ALL were positive. Only one of the 26 cases of AML gave
a borderline inhibition, and only one of the 10 cases of AUL
gave a significant inhibition of 51%.
Furthermore, sera from six patients with c-ALL were tested
before treatment and after induction of complete remission.
A marked drop of the CALLA values after treatment was
observed in the four cases who had elevated values at presen-
tation (Fig. 3).
In two c-ALL cases in which serum as well as EDTA and
heparin plasma samples were obtained and separated from
blood at different time intervals after blood collection (1, 24,
and 48 h), we did not observe any difference in CALLA
inhibition, neither between serum and plasma values nor
between samples prepared by early or late centrifugations.
These results suggest that the CALLA detected in serum or
plasma has not been released from blood cells after blood
collection.
Serum samples from six patients with elevated CALLA
inhibition values were centrifuged at 100,000 g for 1 h at 40C.
The CALLA was measured by RIA both in the supernatant
and the pellets. Virtually all of the CALLA inhibiting activity
(95-100%) was found in the pellet fractions. In addition, pellet
and supernatant fractions from CALLA-positive sera were
tested for the presence of 5'-nucleotidase, an enzyme known
to be associated with cell membrane (20). Again, 100% of the
enzyme activity was detected in the pellet, with values ranging
from 200 to 5,000 nmol/h per mg of protein. Together, these
results suggest that the CALLA detected in the serum of c-
















Figure 3. Comparison of serum CALLA levels before treatment and
after clinical remission in six patients with c-ALL. Each line joins the
two values from the same patient.
Discussion
In this context, it is of interest that a release of Ia antigens in
the supernatant of cultured murine B-cell lymphomas has
been observed (22). In this case also, the released antigen was
recovered in the pellet after a centrifugation at 100,000 g.
The clinical significance of circulating CALLA remains to
be ascertained. Along this line, it should be emphasized that
all the cases of c-ALL tested here had been diagnosed by
previous bone marrow examination and had >90% leukemia
blasts. However, some of the cases had relatively low numbers
of leukemic blasts in peripheral blood. There was no correlation
between the CALLA levels in the serum and the number of
malignant cells in the circulation. For instance, six cases with
CALLA inhibition values ranging from 40 to 88% (mean
= 53) had <5,000 blasts/fl of blood (mean = 1,900); whereas
four cases with >20,000 blasts/,l of blood (mean = 37,800)
had < 35% of CALLA inhibition value (mean = 24). This
absence of correlation suggests that the major part of the
CALLA material detected in the circulation is released by
noncirculating leukemic cells. An alternative explanation could
be that the blasts from each case of c-ALL have a different
rate of CALLA release.
Prospective and sequential CALLA assays should be per-
formed in the serum of patients with c-ALL in remission to
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determine how early in the relapse this antigen becomes
detectable in the circulation, and if sequential CALLA assays
could substitute for some of the repeated bone marrow aspi-
rations.
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